Independent data about the safety and efficacy of rivaroxaban for prevention of stroke/embolism are needed: Author reply

Affiliations

¹ Center for Vascular Medicine and Department of Medicine III, Division of Angiology, University Hospital 'Carl Gustav Carus' Dresden, Fetscherstrasse 74, Dresden D-01307, Germany jan.beyer@uniklinikum-dresden.de.

Comment

Jan Beyer-Westendorf. Europace. 2016 Jan.

. 2016 Jan;18(1):156-8.

doi: 10.1093/europace/euv286. Epub 2015 Dec 30.

¹ Center for Vascular Medicine and Department of Medicine III, Division of Angiology, University Hospital 'Carl Gustav Carus' Dresden, Fetscherstrasse 74, Dresden D-01307, Germany jan.beyer@uniklinikum-dresden.de.

No abstract available

Comment on

Drug persistence with rivaroxaban therapy in atrial fibrillation patients-results from the Dresden non-interventional oral anticoagulation registry.
Beyer-Westendorf J, Förster K, Ebertz F, Gelbricht V, Schreier T, Göbelt M, Michalski F, Endig H, Sahin K, Tittl L, Weiss N. Beyer-Westendorf J, et al. Europace. 2015 Apr;17(4):530-8. doi: 10.1093/europace/euu319. Epub 2015 Feb 17. Europace. 2015. PMID: 25694537 Free PMC article.
Independent data about the safety and efficacy of rivaroxaban for prevention of stroke/embolism are needed.
Stöllberger C, Pommer P, Schneider B, Finsterer J. Stöllberger C, et al. Europace. 2016 Jan;18(1):156. doi: 10.1093/europace/euv277. Epub 2015 Dec 30. Europace. 2016. PMID: 26718534 No abstract available.